Autoimmune hemolysis (AH) and immune thrombocytopenic purpura (ITP) are recognized complications after cord blood transplantation (CBT). We evaluated the incidence and characteristics of AH/ITP after double-unit CBT in a day 100 landmark analysis of 152 patients (median age 36 years, range 0.9–70 years) transplanted for hematologic malignancies with myeloablative or nonmyeloablative conditioning and calcineurin inhibitor (CNI)/mycophenolate mofetil. With a median 5.2-year (range 1.6–9.7 years) survivor follow-up, 10 patients developed autoimmune cytopenias (8 AH, 1 ITP, 1 both) at a median of 10.4 months (range 5.8–24.5) post CBT for a 7% cumulative incidence 3 years after the day 100 landmark. Six patients presented with severe disease (hemoglobin ⩽6 g/dL and/or platelets <20 × 109/L). All AH patients were direct antiglobulin test positive. All 10 cases developed during immunosuppression taper with 8 having prior acute GVHD. All 10 patients received rituximab 2–18 days after diagnosis, and corticosteroids combined with rituximab within <7 days was the most effective. No patient died of AH/ITP. AH/ITP occurs infrequently after CBT but may be life-threatening requiring emergency therapy. Rituximab combined with corticosteroids at diagnosis is warranted in patients with severe disease.
Autoimmune complications including autoimmune hemolytic anemia (AH) and immune thrombocytopenic purpura (ITP) are well recognized after hematopoietic stem cell transplantation.1, 2, 3, 4, 5 A recent retrospective registry analysis described the development of autoimmune diseases after cord blood transplantation (CBT).6 The overall incidence of autoimmune disease was 5% and most commonly manifested as AH or ITP. However, the literature describing the manifestations of AH and ITP after CBT is limited and the optimal therapy is not established.7, 8, 9, 10, 11 We performed a retrospective study to characterize the incidence, severity, treatment response and prognosis of these autoimmune cytopenias in CBT recipients transplanted at our center.
Materials and methods
Eligibility for study inclusion included patients who underwent CBT October 2005–June 2014 for the treatment of hematologic malignancies who had sustained donor engraftment and were disease free 100 days post transplant. This landmark was chosen as no patient developed AH/ITP before day 100. Permission to use clinical and laboratory information was obtained from the Memorial Sloan Kettering Cancer Center Institutional Review/Privacy Board.
Conditioning regimens, GVHD prophylaxis and treatment
Conditioning was predominantly cyclophosphamide, fludarabine and TBI based, although a small cohort of pediatric patients received chemotherapy-only preparative regimens. A calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) were used for GVHD prophylaxis.12, 13, 14, 15 All patients received double-unit grafts comprised of two units that were 4–6/6 HLA-A, -B Ag, -DRB1 allele matched to the recipient. No patients during the study period received single unit grafts per MSKCC (Memorial Sloan Kettering Cancer Center) policy. GVHD was diagnosed, graded and treated as described previously.16
AH was diagnosed in the setting of decreasing hemoglobin (Hb), increased lactate dehydrogenase (LDH, range 120–246 U/L), increased unconjugated bilirubin (range 0–1 mg/dL), haptoglobin <1 mg/dL (range 40–240 mg/dL) and a positive direct antiglobulin test (DAT).17, 18 Severe AH was defined as an Hb⩽6 g/dL. Complete response (CR) was sustained increase in Hb>8 g/dL, resolution of markers of hemolysis and independence from blood transfusions. ITP was diagnosed according to standard published criteria in patients with a platelet count <100 × 109/L in the absence of any other causes of thrombocytopenia.19 Analysis of the presence of platelet antibodies was not performed because of its questionable utility in ITP diagnosis.20, 21 Severe ITP was defined as a platelet count <20 × 109/L. CR was characterized by sustained increase in platelet count >100 × 109/L and independence from transfusions.
Competing risks methodology was used to estimate the incidence of AH/ITP following the 100-day landmark. Competing events include relapse or death in the absence of autoimmune cytopenias. Estimation was carried out using the R statistical platform (R Core team, Vienna, Austria).
Characteristics of the dCBT cohort
One hundred and fifty-two patients alive and disease free at day 100 were analyzed. Patient characteristics are described in Table 1. The median age was 37 years (range 0.9–70 years) and 88 (58%) were male. The most common indication for dCBT was acute leukemia (n=94, 62%) and the majority of patients (n=123, 81%) received high-dose or intermediate intensity conditioning. The 29 pediatric patient group in the study had a much lower percentage of recipient CMV seropositivity (31% as compared with 61% in adults) and were almost exclusively transplanted for acute leukemia (28 of 29 children) with myeloablative conditioning. Ninety-seven (64%) patients had grade II–IV aGHVD (71 grade II, 22 grade III, 4 grade IV) by day 100 by IBMTR (International Bone Marrow Transplant Registry) criteria.16 The incidence of chronic GVHD at 1 year post transplant was 17%.
Incidence and features of AH/ITP
With a median 5.2 year (range 1.6–9.7) survivor follow-up after dCBT, 10 patients (median age 42 years, range 2–54) developed autoimmune cytopenias (AH, ITP or both) for a cumulative incidence of 7% (95% confidence interval (CI): 3–11) at 3 years after the day 100 landmark (Figure 1). The median onset was 10.4 months (range 5.8–24.5) post CBT. Eight developed AH, one patient developed ITP alone and one patient had both AH and ITP. The patient characteristics and the features of the AH/ITP are shown in Table 2. Many months before the onset of AH/ITP, all patients had complete donor-derived hematopoietic recovery, were transfusion independent and were documented to be 100% donor chimeric. Alternative reasons for cytopenias such as myelosuppressive drugs or relapse were not present in any patient and no patient had an active infection immediately before or at the time of AH/ITP diagnosis.
All nine patients with AH were polyspecific IgG positive with eluate demonstrating a warm panagglutinin. The lowest Hb (median 5 g/dL, range 2.6–9.0) was observed at a median of 1 day (range 0–94) after diagnosis, and five AH patients had severe disease (Hb ranging 2.6–5.0 g/dL) at presentation. The median peak LDH was 473 U/L and ranged 300–1486 U/L (normal LDH 120–246 U/L) and haptoglobin was <1 mg/dL in all patients. Both patients with ITP presented with severe disease (platelet count undetectable and 4 × 109/L, respectively).
Eight of the 10 patients had a history of grade II–IV acute GVHD prior to the onset of AH/ ITP (Table 2). One patient had grade I skin acute GVHD treated with topical corticosteroids, whereas five patients had grade II and two had grade III treated with either budesonide (n=5) or low-dose prednisone (n=2). The median onset of acute GVHD in these eight patients was 35 days (range 17–175) post transplant. Thus, the median onset of the AH/ITP was many months later than the median time to onset of the AH/ITP. At the time of onset, all 10 AH/ITP patients had either recently tapered off all immune suppression (n=2) or were on low-dose therapy (n=8). There was no association between recipient age, diagnosis, conditioning intensity, ABO mismatch or recipient CMV serostatus and AH/ITP (data not shown).
Treatment and response to therapy
Upon recognition of severe hemolysis and/or thrombocytopenia, all patients received packed red blood cell and/or platelet transfusion support as needed, although all were transfusion refractory owing to the autoimmune process. Treatment during the first week included single agent or combination therapy with IV immune globulin (IVIg), IV methylprednisolone, rituximab (375 mg/m2/dose) or CNI dose escalation (Table 1). All 10 patients received rituximab commencing 2–18 days (4–6 total doses) after initial diagnosis. In six patients (patients 1–6) who received staggered therapy at diagnosis including treatment delay or only IVIg, and received rituximab 7–18 days from diagnosis, the time to CR ranged 19–98 days, and three of six underwent splenectomy. In the four patients (patients 7–10) who were treated with corticosteroids at diagnosis with rituximab within 2–6 days, the time to CR was shorter ranging from 7 to 13 days and none underwent splenectomy.
Patients 2 and 5 underwent splenectomy as part of initial therapy. Patient 2 with ITP was initially treated with IVIg alone followed by weekly rituximab for three doses, dexamethasone (40 mg/day for 4 days) and romiplostim 1–10 μg/kg titrated weekly for five doses. Owing to suboptimal response, splenectomy was performed at 50 days and CR was achieved 98 days after diagnosis. Patient 5 with AH was initially treated with IVIg, and subsequently methylprednisolone. Weekly rituximab for two doses was started 18 days after diagnosis. Splenectomy was performed at 39 days followed by further rituximab weekly for two doses and continuation of prednisone. CR was documented at 61 days after diagnosis. In all patients, the recovery from AH was accompanied by correction of biochemical parameters associated with hemolysis.
Patients 1, 3, 4 and 8 flared at 1–13 months after initial CR. All patients received additional rituximab (2–4 doses)±additional corticosteroids and/or IVIg. Patients 1, 4 and 8 achieved CR with pharmacologic therapy. Patient 3 required splenectomy to achieve control of AH with CR documented 4 months later but recurrent flares have required ongoing corticosteroid therapy. There was no recurrent GVHD in any of the four patients who flared their AH/ITP.
Survival and adverse events
Nine of 10 patients with AH/ITP patients are alive and disease free, whereas one (patient 5) died of GVHD in CR from AH. Eight of the nine surviving patients remain in CR from AH/ITP at a median of 1.8 years after AH/ITP diagnosis (range 0.9–8.6). Rituximab treatment was well tolerated. After rituximab, one patient developed severe neutropenia (<0.5 × 109/L) documented once, and two additional patients became neutropenic (lowest counts 1.0–1.5 × 109/L, respectively). All three patients received filgrastim and promptly responded within <7 days. Four patients required transient IVIg repletion Patients received mold prophylaxis for the period of high-dose corticosteroids. All patients were still on herpes simplex/zoster and pneumocystis prophylaxis at the time of AH/ITP onset and these were continued as guided by the patients’ immune reconstitution. Additionally, patients who underwent splenectomy were placed on long-term prophylaxis for encapsulated organisms. With this prophylaxis, no patient developed an infection attributable to AH/ITP therapy. Patient 5 did develop multiple infections post-AH therapy but this was in the context of active GVHD therapy. This patient was not neutropenic but had undergone splenectomy. The infections were not directly attributable to rituximab but were attributable to GVHD and severe T-cell immune compromise.
Notably, all three patients who underwent splenectomy required intensive care unit transfer during the course of their surgery. Two patients required perisurgical intensive care unit management owing to the requirement for complex medical care including IV medications, hydration, narcotics, antibiotics and intensive transfusion needs, whereas in one AH patient despite a normal platelet count, the splenectomy was complicated by life-threatening postoperative hemorrhage into the splenic bed.
We analyzed the incidence, characteristics and outcome of autoimmune cytopenias after dCBT in a large, predominantly adult population. Although occurring infrequently (7% at 3 years after the day 100 landmark), the autoimmune cytopenias are often of sudden onset and may be life-threatening. Of the 10 patients, six had an Hb ranging from 2 to 5 g/dL and/or platelets <5 × 109/L, and in both settings these severe cytopenias were unsupportable by red blood cell and/or platelet transfusions. The fact that the median onset of this complication is relatively late post transplant is of further concern as patients may be undergoing less frequent follow-up and returned to community physicians away from the transplant center. Most of the patients had a prior history of acute GVHD and all autoimmune cytopenias occurred in the setting of immunosuppression taper. This suggests that the mechanism is related to transient immune dysregulation and highlights the need for monitoring of CBT recipients during this period of highest risk.
Although treatment in this series was not standardized, all 10 patients received rituximab 2–18 days after diagnosis. The most effective therapy was corticosteroids at diagnosis combined with rituximab within 2–6 days (patients 7–10). By contrast, serial or staggered therapy (patients 1–6) was less successful. Outcome of AH/ITP patients was good and no patient died of autoimmune cytopenia. Rituximab treatment was well tolerated, although transient support with IVIg and/or growth factor may be necessary. However, all three patients who underwent splenectomy in this series required intensive care unit transfer.
The incidence of AH/ITP in our analysis is similar to the rates of autoimmune cytopenias published in single center studies after adult donor allograft recipients.1, 2, 4, 5, 22 For example, a 4.4% cumulative incidence of AH has been reported in adult allogenic transplant recipients at 3 years. Multivariate analysis identified the presence of chronic GVHD, use of unrelated donors, T-cell depletion and concomitant viral infections as risk factors.3 In contrast to our report in adult CBT recipients, Page et al.8 reported a 52% incidence of autoimmune cytopenia in a small cohort of very young infants 2 years after CBT. Conversely, Sanz et al.11 has reported a 5.4% incidence of AH and 1.4% incidence of ITP in adult single unit CBT recipients 3 years post transplant. In contrast to our report, the majority of AH patients in this analysis had cold agglutinins, concomitant viral infections and chronic GVHD, and this complication was associated with a high mortality.
Overall, the retrospective nature of this series is a limitation of this report and a large prospective randomized controlled trial would be required to define AH/ITP risk factors and its optimal therapy. However, such studies are unlikely to be performed given the uncommon nature of this complication. In the interim, vigilance for this potentially life-threatening complication with early treatment with combined corticosteroids and rituximab is warranted in patients with severe disease. Our hypothesis is that this combined initial therapy will both speed response and ultimately lessen the duration of corticosteroid therapy permitting a more rapid and effective corticosteroid taper. Limitation of corticosteroid exposure as much as possible in this patient population is critical due to their risk of serious viral and fungal infections including CMV and mold, as well as other toxicities such as Cushingoid facies, steroid myopathy, osteopenia and diabetes. Early rituximab could also potentially avoid the requirement for splenectomy in most patients. While rituximab did not avoid flares in all patients, it is possible that early rituximab with four doses could also potentially reduce the likelihood of disease flare upon corticosteroid taper in many. For these reasons, a course of rituximab combined with corticosteroids at diagnosis is now the standard of care for CBT recipients with AH/ITP at our center with rapid corticosteroid taper once CR is achieved.
Drobyski WR, Potluri J, Sauer D, Gottschall JL . Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1093–1099.
Chen FE, Owen I, Savage D, Roberts I, Apperley J, Goldman JM et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant 1997; 19: 491–495.
Sanz J, Arriaga F, Montesinos P, Orti G, Lorenzo I, Cantero S et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant 2007; 39: 555–561.
Daikeler T, Tyndall A . Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007; 20: 349–360.
Holbro A, Abinun M, Daikeler T . Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol 2012; 157: 281–290.
Daikeler T, Labopin M, Ruggeri A, Crotta A, Abinun M, Hussein AA et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2013; 121: 1059–1064.
Radhi M, Rumelhart S, Tatman D, Goldman F . Severe autoimmune hemolytic anemia after unrelated umbilical cord blood transplant for familial hemophagocytic lymphohistiocytosis: significant improvement after treatment with rituximab. J Pediatr Hematol Oncol 2007; 29: 125–127.
Page KM, Mendizabal AM, Prasad VK, Martin PL, Parikh S, Wood S et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant 2008; 14: 1108–1117.
Chao MM, Levine JE, Ferrara JL, Cooling L, Cooke KR, Hutchinson RJ et al. Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H. Pediatr Blood Cancer 2008; 50: 917–919.
Nomura S, Ishii K, Inami N, Matsuzaki T, Yamaoka M, Urase F et al. Antiglycoprotein IIb–IIIa autoantibody in a patient with immune thrombocytopenia after cord blood transplantation. Clin Appl Thromb Hemost 2009; 15: 123–124.
Sanz J, Arango M, Carpio N, Montesinos P, Moscardo F, Martin G et al. Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. Bone Marrow Transplant 2014; 49: 1084–1088.
Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1316–1326.
Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biol Blood Marrow Transplant 2013; 19: 799–803.
Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD et al. Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant 2013; 19: 904–911.
Harnicar S, Ponce DM, Hilden P, Zheng J, Devlin SM, Lubin M et al. Intensified mycophenolate mofetil dosing and higher mycophenolic acid trough levels reduce severe acute graft-versus-host disease after double-unit cord blood transplantation. Biol Blood Marrow Transplant 2015; 21: 920–925.
Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–864.
Bass GF, Tuscano ET, Tuscano JM . Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev 2014; 13: 560–564.
Zantek ND, Koepsell SA, Tharp DR Jr, Cohn CS . The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol 2012; 87: 707–709.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190–4207.
Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH . Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996; 88: 194–201.
Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG . A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999; 104: 442–447.
Penalver FJ, Alvarez-Larran A, Diez-Martin JL, Gallur L, Jarque I, Caballero D et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010; 89: 1073–1080.
This work was supported, in part, by the Gabrielle’s Angel Foundation for Cancer Research (to JNB), the Society of Memorial Sloan Kettering Cancer Center (to JNB and SG), the Memorial Sloan Kettering Cancer Center Translational and Integrative Medicine Research Program (to JNB), P01 CA23766 from the National Cancer Institute, National Institutes of Health and the Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).
The authors declare no conflict of interest.
About this article
Cite this article
Bhatt, V., Shune, L., Lauer, E. et al. Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab. Bone Marrow Transplant 51, 1579–1583 (2016). https://doi.org/10.1038/bmt.2016.228
Immune-Mediated Cytopenias After Hematopoietic Cell Transplantation: Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment Strategies
Current Oncology Reports (2019)
Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation
Bone Marrow Transplantation (2019)
Biology of Blood and Marrow Transplantation (2019)
Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature
Pediatric Blood & Cancer (2018)
Biology of Blood and Marrow Transplantation (2017)